Injection Influenza Vaccine Market Research Report
On Oct 28, the latest report "Global Injection Influenza Vaccine Market 2025 by Manufacturers, Regions, Types and Applications, Forecast to 2031" from Global Info Research provides a detailed and comprehensive analysis of the global Injection Influenza Vaccine market. The report provides both quantitative and qualitative analysis by manufacturers, regions and countries, types and applications. As the market is constantly changing, this report explores market competition, supply and demand trends, and key factors that are causing many market demand changes. The report also provides company profiles and product examples of some of the competitors, as well as market share estimates for some of the leading players in 2025.
Get Report Sample with Industry Insights https://www.globalinforesearch.com/reports/3075480/injection-influenza-vaccine
According to our (Global Info Research) latest study, the global Injection Influenza Vaccine market size was valued at US$ 9399 million in 2024 and is forecast to a readjusted size of USD 13789 million by 2031 with a CAGR of 5.4% during review period.
In this report, we will assess the current U.S. tariff framework alongside international policy adaptations, analyzing their effects on competitive market structures, regional economic dynamics, and supply chain resilience.
The Injection Influenza Vaccine refers to an inactivated or recombinant protein vaccine administered via intramuscular or subcutaneous injection to prevent seasonal influenza infections caused by influenza A and B viruses. It functions by inducing a specific immune response against viral surface antigens—such as hemagglutinin (HA) and neuraminidase (NA)—to enable rapid pathogen clearance, alleviate symptoms, and reduce complications and mortality after exposure. Today, it represents one of the most widely adopted preventive biologics worldwide, used extensively among high-risk populations such as children, the elderly, pregnant women, and patients with chronic diseases. With advances in mRNA platforms, recombinant protein technology, and adjuvant optimization, the vaccine’s durability, safety, and antigenic coverage continue to improve, steering the industry toward efficient, personalized, and lifelong influenza protection.In 2024, global Injection Influenza Vaccine production reached approximately 842 m units, with an average global market price of around US$ 10.8 perunit. The average gross profit margin for this product is 57% and global capacity is about 900 million units.
The continuous strengthening of global public health systems and institutionalized vaccination programs across countries are fostering long-term growth for the injection influenza vaccine market. Post-COVID-19, public awareness of respiratory virus prevention has risen significantly, driving record-high influenza vaccination rates. The development of multivalent and recombinant technologies enhances strain coverage, immune durability, and population protection. In addition, governments are increasing investment in domestic vaccine production capacity and cold-chain infrastructure, boosting upstream and logistical sectors.
Despite stable demand growth, the industry faces challenges such as lengthy production cycles, strain-matching uncertainty, and intensified price competition. The high mutation rate of influenza viruses requires annual strain updates, adding production uncertainty and inventory risks. In many developing regions, vaccination infrastructure remains weak, limiting market penetration. The market is also characterized by high concentration among major global producers, creating high entry barriers and regulatory costs for new players. Continued public scrutiny over vaccine safety further tests consumer confidence.
Market demand is shifting from “seasonal prevention” to “year-round immunization,” with growing emphasis on routine and differentiated vaccination strategies. Aging populations are significantly increasing vaccination rates among adults and the elderly. Corporate and educational institutions are incorporating influenza prevention into annual health management plans, boosting group immunization demand. Moreover, next-generation vaccines featuring needle-free delivery, lower doses, and rapid immune response are encouraging clinics and retail pharmacies to expand vaccination services.
Production of injection influenza vaccines depends on high-quality embryonated chicken eggs or cell culture substrates, antigen purification reagents, adjuvants, and sterile packaging systems. The growing adoption of cell-based vaccine technologies (e.g., MDCK, Vero) has improved production efficiency and stability, reducing reliance on traditional egg-based processes. Upstream material supply is increasingly moving toward customization and biosafety standardization—such as animal-free media and ultra-pure lipid adjuvants—to meet stringent global regulatory requirements for traceability and consistency.
This report is a detailed and comprehensive analysis for global Injection Influenza Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approval.
Injection Influenza Vaccine market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type: Trivalent Influenza Vaccine、 Quadrivalent Influenza Vaccine
Market segment by Application: 6 Months to 3 Years、 > 3 Years
Major players covered: Sanofi、 CSL、 GSK、 Viatris、 AstraZeneca、 Hualan Bio、 Changchun Institute of Biological、 Sinovac、 BCHT、 Jiangsu GDK、 KM Biologics
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Injection Influenza Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Injection Influenza Vaccine, with price, sales quantity, revenue, and global market share of Injection Influenza Vaccine from 2020 to 2025.
Chapter 3, the Injection Influenza Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Injection Influenza Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment Injection Influenza Vaccine the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the Injection Influenza Vaccine sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2024.and Injection Influenza Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Injection Influenza Vaccine.
Chapter 14 and 15, to describe Injection Influenza Vaccine sales channel, distributors, customers, research findings and conclusion.
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Injection Influenza Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
Global Info Research is a company that digs deep into global industry information to support enterprises with market strategies and in-depth market development analysis reports. We provides market information consulting services in the global region to support enterprise strategic planning and official information reporting, and focuses on customized research, management consulting, IPO consulting, industry chain research, database and top industry services. At the same time, Global Info Research is also a report publisher, a customer and an interest-based suppliers, and is trusted by more than 30,000 companies around the world. We will always carry out all aspects of our business with excellent expertise and experience.
Contact Us:
Global Info Research
Web: https://www.globalinforesearch.com
Email: report@globalinforesearch.com
CN: 0086-176 6505 2062
HK: 00852-58030175
Get Report Sample with Industry Insights https://www.globalinforesearch.com/reports/3075480/injection-influenza-vaccine
According to our (Global Info Research) latest study, the global Injection Influenza Vaccine market size was valued at US$ 9399 million in 2024 and is forecast to a readjusted size of USD 13789 million by 2031 with a CAGR of 5.4% during review period.
In this report, we will assess the current U.S. tariff framework alongside international policy adaptations, analyzing their effects on competitive market structures, regional economic dynamics, and supply chain resilience.
The Injection Influenza Vaccine refers to an inactivated or recombinant protein vaccine administered via intramuscular or subcutaneous injection to prevent seasonal influenza infections caused by influenza A and B viruses. It functions by inducing a specific immune response against viral surface antigens—such as hemagglutinin (HA) and neuraminidase (NA)—to enable rapid pathogen clearance, alleviate symptoms, and reduce complications and mortality after exposure. Today, it represents one of the most widely adopted preventive biologics worldwide, used extensively among high-risk populations such as children, the elderly, pregnant women, and patients with chronic diseases. With advances in mRNA platforms, recombinant protein technology, and adjuvant optimization, the vaccine’s durability, safety, and antigenic coverage continue to improve, steering the industry toward efficient, personalized, and lifelong influenza protection.In 2024, global Injection Influenza Vaccine production reached approximately 842 m units, with an average global market price of around US$ 10.8 perunit. The average gross profit margin for this product is 57% and global capacity is about 900 million units.
The continuous strengthening of global public health systems and institutionalized vaccination programs across countries are fostering long-term growth for the injection influenza vaccine market. Post-COVID-19, public awareness of respiratory virus prevention has risen significantly, driving record-high influenza vaccination rates. The development of multivalent and recombinant technologies enhances strain coverage, immune durability, and population protection. In addition, governments are increasing investment in domestic vaccine production capacity and cold-chain infrastructure, boosting upstream and logistical sectors.
Despite stable demand growth, the industry faces challenges such as lengthy production cycles, strain-matching uncertainty, and intensified price competition. The high mutation rate of influenza viruses requires annual strain updates, adding production uncertainty and inventory risks. In many developing regions, vaccination infrastructure remains weak, limiting market penetration. The market is also characterized by high concentration among major global producers, creating high entry barriers and regulatory costs for new players. Continued public scrutiny over vaccine safety further tests consumer confidence.
Market demand is shifting from “seasonal prevention” to “year-round immunization,” with growing emphasis on routine and differentiated vaccination strategies. Aging populations are significantly increasing vaccination rates among adults and the elderly. Corporate and educational institutions are incorporating influenza prevention into annual health management plans, boosting group immunization demand. Moreover, next-generation vaccines featuring needle-free delivery, lower doses, and rapid immune response are encouraging clinics and retail pharmacies to expand vaccination services.
Production of injection influenza vaccines depends on high-quality embryonated chicken eggs or cell culture substrates, antigen purification reagents, adjuvants, and sterile packaging systems. The growing adoption of cell-based vaccine technologies (e.g., MDCK, Vero) has improved production efficiency and stability, reducing reliance on traditional egg-based processes. Upstream material supply is increasingly moving toward customization and biosafety standardization—such as animal-free media and ultra-pure lipid adjuvants—to meet stringent global regulatory requirements for traceability and consistency.
This report is a detailed and comprehensive analysis for global Injection Influenza Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approval.
Injection Influenza Vaccine market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type: Trivalent Influenza Vaccine、 Quadrivalent Influenza Vaccine
Market segment by Application: 6 Months to 3 Years、 > 3 Years
Major players covered: Sanofi、 CSL、 GSK、 Viatris、 AstraZeneca、 Hualan Bio、 Changchun Institute of Biological、 Sinovac、 BCHT、 Jiangsu GDK、 KM Biologics
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Injection Influenza Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Injection Influenza Vaccine, with price, sales quantity, revenue, and global market share of Injection Influenza Vaccine from 2020 to 2025.
Chapter 3, the Injection Influenza Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Injection Influenza Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment Injection Influenza Vaccine the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the Injection Influenza Vaccine sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2024.and Injection Influenza Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Injection Influenza Vaccine.
Chapter 14 and 15, to describe Injection Influenza Vaccine sales channel, distributors, customers, research findings and conclusion.
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Injection Influenza Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
Global Info Research is a company that digs deep into global industry information to support enterprises with market strategies and in-depth market development analysis reports. We provides market information consulting services in the global region to support enterprise strategic planning and official information reporting, and focuses on customized research, management consulting, IPO consulting, industry chain research, database and top industry services. At the same time, Global Info Research is also a report publisher, a customer and an interest-based suppliers, and is trusted by more than 30,000 companies around the world. We will always carry out all aspects of our business with excellent expertise and experience.
Contact Us:
Global Info Research
Web: https://www.globalinforesearch.com
Email: report@globalinforesearch.com
CN: 0086-176 6505 2062
HK: 00852-58030175
